Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01714102 · ClinicalTrials.gov registry record · NA

Resveratrol and the Metabolic Syndrome

A NA study of Obesity and Insulin Resistance, sponsored by Rockefeller University.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT01714102: Completed NA study of Obesity and Insulin Resistance, sponsored by Rockefeller University.

NCT01714102 is a NA study of Obesity and Insulin Resistance that has completed, run by Rockefeller University. The registered enrollment target is 28 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01714102, a NA study of Obesity and Insulin Resistance, has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

Metabolic syndrome is a serious health condition that affects about 35 percent of adults and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases related to fatty buildups in artery walls. The underlying causes of metabolic syndrome are obesity, being overweight, physical inactivity and genetic factors. In recent decades, the prevalence has increased dramatically in the United States. Lifestyle interventions including dietary modification, physical activity and weight loss form the basis of treatment for these patients. However, research has shown that even when people are able to incorporate these changes, they often revert back to their usual lifestyle resulting in weight gain and continued risk for diabetes and heart disease. Resveratrol, a natural plant derived compound found in grapes, peanuts and red wine, has been found to reverse some of the features of the metabolic syndrome (insulin resistance, high triglycerides, high blood pressure) in rodents. These improvements occurred without weight loss, and were proven to be a direct result of resveratrol ingestion. Other studies reveal improvement in cardiovascular health, tumor suppression, and longevity. However, there are few studies investigating these beneficial effects in humans. Investigators propose to prove that resveratrol, administered to subjects with the metabolic syndrome, under controlled conditions of weight stability, common diet, and strict compliance with the study drug, will improve the symptoms of the metabolic syndrome, thereby decreasing the chance of developing diabetes or heart disease.

Primary Outcome

Investigators anticipate resveratrol will have positive effect (ie reduction) on Insulin resistance as determined by Euglycemic hyperinsulinemic clamp

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Resveratrol

Study Locations (1)

New York

  • The Rockefeller University - New York

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2012-10
Est. Completion 2018-07
Phase NA
Rockefeller University

117 total trials

What the finished NCT01714102 record still lists

NCT01714102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01714102 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01714102 about?

NCT01714102 is a clinical study titled "Resveratrol and the Metabolic Syndrome". Metabolic syndrome is a serious health condition that affects about 35 percent of adults and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases related to fatty buildups in artery walls. The underlying causes of metabolic syndrome are obesity, being overweight, physi...

What is the current status of trial NCT01714102?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2012-10. Estimated completion is 2018-07.

What conditions does trial NCT01714102 study?

This clinical trial studies the following conditions: Obesity, Insulin Resistance, Metabolic Syndrome.

What interventions are being tested in trial NCT01714102?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resveratrol (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01714102?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01714102 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01714102's enrollment target sits among peer trials

28 886th of 1053 higher than 162 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01714102, the US trial registry maintained by the National Library of Medicine. NCT01714102 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.